Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Incyte Corporation's SEC filings document a Nasdaq-listed biopharmaceutical issuer with common stock trading under INCY and product franchises in hematology, oncology, and inflammation and autoimmunity. Form 8-K reports cover operating results, product sales trends for Jakafi and Opzelura, financial guidance, pipeline updates, and regulatory correspondence affecting drug applications.
Proxy and current-report filings also disclose board and executive changes, officer appointments, equity compensation, shareholder voting matters, executive pay, governance practices, and registered security information. These filings frame Incyte's capital structure, leadership oversight, commercial portfolio, clinical-development programs, and regulatory risks.
Thomas R. Tray filed a Form 144 notifying a proposed disposition of 2,639 common shares of INCY via a stock option exercise. The filing lists the sale method as Cash through the issuer on 06/04/2026. The notice also records a prior sale of 2,051 shares on 05/26/2026 for $199,664.85.
INCYTE CORP executive Pablo J. Cagnoni reported a tax-related share disposition. On the settlement of previously granted restricted stock units, 25,469 shares of common stock were automatically withheld by the company to cover tax withholding obligations at a price of $95.59 per share. After this withholding, he directly holds 240,848 shares, and this figure includes 213,078 shares tied to unvested restricted stock units and earned performance shares.
INCYTE CORP Principal Accounting Officer Tray Thomas reported an open-market sale of 2,051 shares of common stock at $97.35 per share. After this transaction, Thomas directly holds 21,132 shares. A footnote states that these holdings include 15,166 shares issuable from previously reported, unvested restricted stock units.
INCYTE CORP director Jean-Jacques Bienaimé reported routine equity compensation activity. On May 26, 2026, he exercised 15,000 shares of non-qualified stock options at an exercise price of $84.53 per share, converting an option award into common stock.
On the same date, 13,059 shares of common stock were automatically withheld by the company at $97.10 per share to cover the cost of exercising the option and related tax obligations, rather than being sold in the open market. The filing also notes previously reported restricted stock units that have not yet vested.
Morgan Stanley Smith Barney LLC Executive Financial Services reported a proposed sale of Common shares of INCY via a Form 144 filed 05/26/2026. The filing lists multiple lots tied to Restricted Stock dated 07/02/2023 and Employee Stock Purchase Plan dated 04/30/2025, with specific share line items shown.
INCYTE CORP director Paul J. Clancy completed an option exercise and share sale. On May 19, 2026, he exercised non-qualified stock options to acquire 15,000 shares of common stock at $84.53 per share and sold 15,000 shares at $94.93 per share in an open-market transaction.
After these transactions, he directly owned 23,741 shares of common stock. This figure includes 2,518 shares issuable from previously reported restricted stock units that have not yet vested.
Stein Steven H reported acquisition or exercise transactions in this Form 4 filing.
Incyte Corp chief medical officer Steven H. Stein reported an amended insider transaction showing he earned 44,124 shares of common stock tied to performance shares. The compensation committee determined on May 6, 2026 that specified development, revenue and market-based goals had been achieved.
The earned shares will vest on the third anniversary of the July 14, 2023 grant date, as long as he continues serving the company. Including this certification, Stein now has 78,327 shares of common stock issuable from previously reported restricted stock units and earned performance shares that have not yet vested.
INCYTE CORP reported that President and Global Head of R&D Pablo J. Cagnoni acquired 31,517 shares of common stock through a grant of earned performance shares on May 6, 2026. These shares relate to performance criteria determined to be satisfied on that date and carry no purchase price.
The earned shares will vest on the third anniversary of the original July 14, 2023 grant date, if he continues serving the company. Over the three-year performance period, the number of shares he may receive ranges from 0% to 150% of the performance shares awarded, based on development, revenue and market-based goals tied to relative total shareholder returns versus the Nasdaq Biotechnology Index.
After this certification, Cagnoni holds 266,317 shares directly, including 261,178 shares of common stock issuable from previously reported restricted stock units and earned but unvested performance shares. This Form 4/A amends an earlier filing to reflect the Compensation Committee’s updated performance determination on May 6, 2026.
Incyte Corporation: Institutional ownership update. Dodge & Cox reports beneficial ownership of 12,252,356 shares of Incyte Corporation, representing 6.2% of the class. The filer reports sole voting power for 11,646,204 shares and sole dispositive power for 12,252,356 shares. The filing states these shares are held on behalf of Dodge & Cox clients.